Tibet Rhodiola Pharmaceutical Holding

Tibet Rhodiola Pharmaceutical Holding EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Tibet Rhodiola Pharmaceutical Holding (600211.SS) as of Oct 18, 2026 is 10.73. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 11.60 — a change of -7.49% (lower).

EV/FCF

10.73

YoY

-7.49%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Tibet Rhodiola Pharmaceutical Holding is 2025 10.73 . EV/FCF (Enterprise Value to Free Cash Flow) of Tibet Rhodiola Pharmaceutical Holding was 2024 11.60 . It decreases by -7.49% lower compared to the previous year.

The Tibet Rhodiola Pharmaceutical Holding EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
48.62 CNY
Jan 1, 2019
28.65 CNY
Jan 1, 2020
61.30 CNY
Jan 1, 2021
-214.91 CNY
Jan 1, 2022
16.33 CNY
Jan 1, 2023
10.92 CNY
Jan 1, 2024
11.60 CNY
Jan 1, 2025
10.73 CNY
The Tibet Rhodiola Pharmaceutical Holding EV/FCF history
YEAREV/FCFYoY
10.73-7.49%
11.60+6.21%
10.92-33.13%
16.33-107.60%
-214.91-450.61%
61.30+113.93%
28.65-41.07%
48.62-291.13%
-25.44-144.12%
57.65-46.08%
106.92-236.24%
-78.48—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Tibet Rhodiola Pharmaceutical Holding Stock analysis

What does Tibet Rhodiola Pharmaceutical Holding do? Tibet Rhodiola Pharmaceutical Holding Co, listed on the Shanghai Stock Exchange under ticker 600211.SS, operates as a pharmaceutical company based in Lhasa, China. The company's ISIN is CNE000000ZW7. Founded through an IPO on July 21, 1999, it specializes in the manufacture and wholesale of pharmaceutical products. Its headquarters are located in Lhasa, Xizang, and it employs 615 full-time staff. The firm distributes proprietary drug products and processes pharmaceuticals, conducting business primarily across South China, North China, East China, Central China, and overseas markets. The company's website is http://www.xzyy.cn. It does not provide details on specific products, acquisitions, or financial figures beyond the IPO date and employee count. The company focuses on pharmaceutical manufacturing and distribution within its operational regions, with no additional information provided on its product lines or market share. Tibet Rhodiola Pharmaceutical Holding is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tibet Rhodiola Pharmaceutical Holding stock

EV/FCF (Enterprise Value to Free Cash Flow) of Tibet Rhodiola Pharmaceutical Holding is 10.73 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Tibet Rhodiola Pharmaceutical Holding changed from 11.60 to 10.73, representing a -7.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Tibet Rhodiola Pharmaceutical Holding since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Tibet Rhodiola Pharmaceutical Holding with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Tibet Rhodiola Pharmaceutical Holding

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Tibet Rhodiola Pharmaceutical Holding